Rhabdomyosarcoma Market is Expected to Rise Throughout Forecast Period (2025-2034) with Promising Drug Candidates in Pipeline | DelveInsight ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

Consciousness is fundamental; only thereafter do time, space and matter arise. This is the starting point for a new theoretical model of the nature of reality, presented by Maria Strømme, Professor of ...

It’s nearly December, which means a host of prediction stories will soon flood the lookahead debate. Why not get started a ...

Machine learning is increasingly recognized as a pivotal tool in the evolution of cardiovascular medicine, promising to ...

Simon Donald Stewart works for the Cawthron Institute. He receives funding from the Ministry of Business, Innovation and Employment (Grant No CAWX2305 and C01X2205). The 19th-century American ...

Diffuse large B-cell lymphoma (DLBCL), the most common type of lymphoma, in most cases is marked by significant heterogeneity and aggressive clinical behavior. While standard chemotherapy often ...

This article may contain affiliate links that Yahoo and/or the publisher may receive a commission from if you buy a product or service through those links. One of the best parts of the warm summer ...

Panelists discuss how new molecular imaging technology offers potential to better risk stratify patients eligible for adjuvant pembrolizumab after surgery, potentially identifying those who have ...

Castle Biosciences, Inc. will present innovative research on cutaneous melanoma (CM) and uveal melanoma (UM) at the 2025 ASCO Annual Meeting in Chicago, showcasing findings from a collaboration with ...

Stratifying patients with the 40-GEP test revealed differences in metastasis-free survival that were not apparent when patients were stratified by NCCN risk group alone or NCCN risk group and BWH ...

Please provide your email address to receive an email when new articles are posted on . Multiple predictors were linked to biochemical or structural evidence of disease 1 year after papillary thyroid ...